Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

This study tests different combinations of hormone-blocking therapy (androgen deprivation), an experimental prostate cancer vaccine (pTVG-AR), and immune checkpoint drugs in men with newly diagnosed high-risk prostate cancer who are candidates for surgery. **You may be eligible if...** - You have confirmed high-risk prostate cancer (Gleason score 7 with PSA above 20, or Gleason score above 7) - You are a candidate for prostate removal surgery - You are in good general health (ECOG 0–1) - You have adequate blood, kidney, and liver function - You have no history of HIV, hepatitis B, or hepatitis C - You have never received prior prostate cancer treatment **You may NOT be eligible if...** - You have had any prior prostate cancer treatment (hormone therapy, radiation, surgery) - You have active heart disease (heart attack or heart failure in last 6 months) - You have an autoimmune disease requiring treatment in the past 2 years - You have had a lung inflammation requiring steroids - You are on high-dose corticosteroids - You received a live vaccine within 14 days - You have a history of severe allergic reactions to tetanus vaccine Talk to your doctor to see if this trial is right for you.